Cambridge-based Ironwood Pharmaceuticals Inc.’s drug to treat irritable bowel syndrome with constipation has won marketing approval in Europe. Linaclotide, for adults, will be launched in Europe next year as Constella. The drug received US approval in August. Ironwood will sell the drug in the United States with a marketing partner, Forest Laboratories, under the brand name Linzess. A Ladenburg Thalmann analyst estimated Constella could bring in revenue of $189 million in 2018.
Constipation drug wins European approval
November 29, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢